Search Results - "Zhen, David B."

The role of molecular testing in pancreatic cancer by Zhen, David B., Safyan, Rachael A., Konick, Eric Q., Nguyen, Ryan, Prichard, Colin C., Chiorean, E. Gabriela

“…Pancreatic ductal adenocarcinoma (PDA) is highly aggressive and has few treatment options. To personalize therapy, it is critical to delineate molecular…”
Get full text

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01 by Sahai, Vaibhav, Griffith, Kent A., Beg, Muhammad S., Shaib, Walid L., Mahalingam, Devalingam, Zhen, David B., Deming, Dustin A., Zalupski, Mark M.

“…Background Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary tract cancer (BTC). The addition of an anti‐programmed death…”
Get full text

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study by Zhen, David B., Rabe, Kari G., Gallinger, Steven, Syngal, Sapna, Schwartz, Ann G., Goggins, Michael G., Hruban, Ralph H., Cote, Michele L., McWilliams, Robert R., Roberts, Nicholas J., Cannon-Albright, Lisa A., Li, Donghui, Moyes, Kelsey, Wenstrup, Richard J., Hartman, Anne-Renee, Seminara, Daniela, Klein, Alison P., Petersen, Gloria M.

“…Purpose: Familial pancreatic cancer kindreds contain at least two affected first-degree relatives. Comprehensive data are needed to assist clinical risk…”
Get full text

Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification by Pratt, Erica D, Cowan, Robert W, Manning, Sara L, Qiao, Edmund, Cameron, Heather, Schradle, Kara, Simeone, Diane M, Zhen, David B

“…Oncology research is increasingly incorporating molecular detection of circulating tumor DNA (ctDNA) as a tool for cancer surveillance and early detection…”
Get full text

Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) by Mohan, Arathi, Griffith, Kent A, Wuchu, Fulei, Zhen, David B, Kumar-Sinha, Chandan, Crysler, Oxana, Hsiehchen, David, Enzler, Thomas, Dippman, Dominique, Gunchick, Valerie, Achreja, Abhinav, Animasahun, Olamide, Choppara, Srinadh, Nenwani, Minal, Chinnaiyan, Arul M, Nagrath, Deepak, Zalupski, Mark M, Sahai, Vaibhav

“…Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical…”
Get full text

Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson by Chaiteerakij, Roongruedee, Petersen, Gloria M, Bamlet, William R, Chaffee, Kari G, Zhen, David B, Burch, Patrick A, Leof, Emma R, Roberts, Lewis R, Oberg, Ann L

“…The inclusion of metformin in the treatment arms of cancer clinical trials is based on improved survival that has been demonstrated in retrospective…”
Get full text

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas by Diehl, Adam C, Hannan, Lindsay M, Zhen, David B, Coveler, Andrew L, King, Gentry, Cohen, Stacey A, Harris, William P, Shankaran, Veena, Wong, Kit M, Green, Steven, Ng, Natasha, Pillarisetty, Venu G, Sham, Jonathan G, Park, James O, Reddi, Deepti, Konnick, Eric Q, Pritchard, Colin C, Baker, Kelsey, Redman, Mary, Chiorean, E Gabriela

“…KRAS variant alleles may have differential biological properties which impact prognosis and therapeutic options in pancreatic ductal adenocarcinomas (PDA). We…”
Get full text

Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma by Zhen, David B., Coveler, Andrew, Zanon, Silvia, Reni, Michele, Chiorean, E. Gabriela

“…Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has…”
Get full text

Hereditary ATTR amyloidosis: a single-institution experience with 266 patients by Swiecicki, Paul L., Zhen, David B., Mauermann, Michelle L., Kyle, Robert A., Zeldenrust, Steven R., Grogan, Martha, Dispenzieri, Angela, Gertz, Morie A.

“…Abstract Background: Hereditary transthyretin amyloidosis (ATTR amyloidosis) is a rare, clinically heterogeneous disease due to heritable mutations that lead…”
Get full text

Combination immunotherapy for pancreatic cancer: challenges and future considerations by Gössling, Gustavo C L, Zhen, David B, Pillarisetty, Venu G, Chiorean, E Gabriela

“…Immune checkpoint inhibitors (ICI) have not yielded significant efficacy in pancreatic ductal adenocarcinoma (PDA), despite the role of the innate and adaptive…”
Get more information

Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma by Coveler, Andrew L, Pillarisetty, Venu G, Koh, Wui-Jin, Zhen, David B, Park, James O, King, Gentry G, Sham, Jonathan G, Hannan, Lindsay M, Mann, Gary N, Baker, Kelsey K, Redman, Mary W, Swanson, Paul E, Chiorean, E Gabriela, Whiting, Sam H

“…Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the United States. Most patients who undergo resection develop…”
Get full text

DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma by Chang, Amy E., Radke, Marc R., Zhen, David B., Baker, Kelsey K., Coveler, Andrew L., Wong, Kit Man, Pillarisetty, Venu G., Reddi, Deepti, Redman, Mary W., Swisher, Elizabeth, Chiorean, Elena Gabriela

Get full text

Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study by Cohen, Stacey A., Veleber, Susan, Siman, Jonathan, Guthrie, Katherine A., McMillen, Kerry, Heit, Madilyn, Wadhera, Sonia, Daniels, Jonathan, Hansen, Kjell, Jacoby, Madeline, Taromina, Katherine, Chin, Samantha, Romeo, Melissa, Langley, Blake O., Coveler, Andrew L., Hannan, Lindsay M., King, Gentry, Purcell, Tom, Safyan, Rachael A., Shankaran, Veena, Zhen, David B., Chiorean, E. Gabriela, Greenlee, Heather

“…Oxaliplatin is a key chemotherapeutic agent in the treatment of local and metastatic gastrointestinal (GI) malignancies. Dose density and treatment adherence…”
Get full text

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer by Zhen, David B., Griffith, Kent A., Ruch, Joshua M., Camphausen, Kevin, Savage, Jason E., Kim, Edward J., Sahai, Vaibhav, Simeone, Diane M., Zalupski, Mark M.

“…Summary Background Cabozantinib and gemcitabine improve tumor control in pancreatic ductal adenocarcinoma (PDAC) in preclinical models through c-Met…”
Get full text

The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients by Dotan, Efrat, Catalano, Paul, Lenchik, Leon, Boutin, Robert, Yao, Xin, Marques, Helga S., Ioffe, Dina, Zhen, David B., Li, Daneng, Wagner, Lynne I., Simon, Melissa A., Wong, Terence Z., O'Dwyer, Peter J.

“…Pancreatic cancer is the fourth leading cause of cancer-related death in the US with an increasing incidence in older adults (OA) over age 70. There are…”
Get full text

Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies by Zhen, David B, McDevitt, Rachel L, Zalupski, Mark M, Sahai, Vaibhav

“…Irinotecan (Camptosar©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies,…”
Get full text

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study by Oh, Do-Youn, He, Aiwu Ruth, Bouattour, Mohamed, Okusaka, Takuji, Qin, Shukui, Chen, Li-Tzong, Kitano, Masayuki, Lee, Choong-Kun, Kim, Jin Won, Chen, Ming-Huang, Suksombooncharoen, Thatthan, Ikeda, Masafumi, Lee, Myung Ah, Chen, Jen-Shi, Potemski, Piotr, Burris, 3rd, Howard A, Ostwal, Vikas, Tanasanvimon, Suebpong, Morizane, Chigusa, Zaucha, Renata E, McNamara, Mairéad G, Avallone, Antonio, Cundom, Juan E, Breder, Valeriy, Tan, Benjamin, Shimizu, Satoshi, Tougeron, David, Evesque, Ludovic, Petrova, Mila, Zhen, David B, Gillmore, Roopinder, Gupta, Vineet Govinda, Dayyani, Farshid, Park, Joon Oh, Buchschacher, Jr, Gary L, Rey, Felipe, Kim, Hyosung, Wang, Julie, Morgan, Claire, Rokutanda, Nana, Żotkiewicz, Magdalena, Vogel, Arndt, Valle, Juan W

“…In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus…”
Get more information

Treatment of Cholesterol Embolization Syndrome in the Setting of an Acute Indication for Anticoagulation Therapy by Kim, Hidong, Zhen, David B, Lieske, John C, McBane, Robert D, Grande, Joseph P, Sandhu, Gurpreet S, Melduni, Rowlens M

“…Cholesterol embolization syndrome (CES) is a complication sometimes occurring after invasive endovascular procedures. CES is characterized by release of…”
Get full text

MO31-4 Phase 1b/2 trial of tucatinib+trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers by Shitara, Kohei, Park, Haeseong, Bekaii-Saab, Tanios, Kim, Sunnie S., Kamath, Suneel, Pishvaian, Michael J., Chen, Christopher, Zhen, David B., Mayor, Joal, Tan, Qianwen, Strickler, John H.

Get full text

Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) by Mohan, Arathi, Griffith, Kent A., Wuchu, Fulei, Zhen, David B., Kumar-Sinha, Chandan, Crysler, Oxana, Hsiehchen, David, Enzler, Thomas, Dippman, Dominique, Gunchick, Valerie, Achreja, Abhinav, Animasahun, Olamide, Choppara, Srinadh, Nenwani, Minal, Chinnaiyan, Arul M., Nagrath, Deepak, Zalupski, Mark M., Sahai, Vaibhav

Get full text